Achieving pathological complete response (pcr) after neoadjuvant chemotherapy significantly improves survival in gastric and esophagogastric junction cancers. Pcr correlates with a 63% lower risk of death (overall survival) using the Becker system. Progression-free survival is similarly improved, with a 38% reduction in risk of progression. Consider prioritizing pcr as a key goal in treatment, especially […]
Category: Upper Gastrointestinal Tract
Predictive factors for success in gastric cancer surgery
Gastric cancer patients with peritoneal metastasis can achieve better outcomes through informed conversion therapy decisions. Study found a 19.4% rate of R0 resection in patients who underwent conversion therapy. Patients receiving conversion surgery had significantly longer median overall survival (p<0.001). High CA125 levels increase the risk of conversion therapy failure (OR: 5.449, p=0.01). For those […]
Hemoglobin-to-albumin ratio predicts complications after gastrectomy
Higher hemoglobin-to-albumin ratios are linked to fewer complications post-radical gastrectomy in gastric cancer patients. A 1-unit increase in the hemoglobin-to-albumin ratio reduces the risk of moderate to severe complications (Clavien-Dindo ≥II) by 62%. This study analyzed data from 352 patients, establishing a clear correlation between nutritional status and surgical outcomes. Monitor hemoglobin-to-albumin ratios to optimize […]
Gastric Cancer Treatment Shift: Prioritizing Patient Outcomes
Gastric cancer with peritoneal metastases is rising, especially in younger patients, highlighting the urgent need for better outcomes. Novel therapies like normothermic intraperitoneal and systemic chemotherapy have shown overall survival benefits. Patient-reported outcomes remain underreported in major trials, with critical insights missed from studies like Dragon-01. Incorporating tailored patient-reported measures into clinical trials is essential […]
New treatment shows promise for refractory GERD patients
Anti-reflux mucosal ablation significantly benefits patients with reflux-predominant GERD unresponsive to PPI therapy. 71.4% of patients receiving mucosal ablation reported at least a 50% improvement in quality of life after 6 months, compared to just 3.6% in the sham group (p<0.001). Significant reductions in heartburn, regurgitation, and reflux episodes were observed, with 35.7% of patients […]
Emerging Techniques for GERD: Long-Term Efficacy Insights
Novel minimally invasive procedures for gastroesophageal reflux disease show promising outcomes, impacting patient selection and surgical approaches. Esophyx and Linx provide long-lasting symptom relief, with sustained quality of life improvements for chronic GERD patients. Stretta shows clinically significant long-term effects on proton pump inhibitor usage and pH monitoring but has limited follow-up data. Surgeons should […]
Social Factors Impact Post-Gastrectomy Outcomes in Cancer Patients
Social determinants significantly affect short-term outcomes after gastrectomy for gastric adenocarcinoma, highlighting disparities in care. Black patients are 25% less likely and Hispanic patients are 29% less likely to experience extended hospital stays compared to white patients. Higher education levels correlate with a 19% increased risk of extended stays and a 26% increased risk of […]
Multimodal Advances Transforming Gastric Cancer Management
Recent updates in multimodal treatment are reshaping gastric cancer care, impacting surgical strategies and patient outcomes. Laparoscopic and robotic gastrectomy are now standard in Asia, supported by major trials like JCOG0912 and K-LASS02. The FLOT chemotherapy regimen is becoming the global standard, while SOX and XELOX gain traction in Asia. Surgeons should consider integrating immunotherapy […]
Efficacy of HIPEC After Laparoscopic Gastrectomy in Gastric Cancer
Laparoscopic gastrectomy plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves outcomes for gastric cancer patients with positive peritoneal lavage cytology. HIPEC-treated patients had significantly lower postoperative recurrence (66.7% vs. 90.9%) and visible metastasis (29.6% vs. 59.1%, p < 0.05). 3-year overall survival for HIPEC patients was 51.8% versus 18.2% for non-HIPEC (p = 0.005). Consider HIPEC for […]
New CT Model Predicts Chemotherapy Response in Stomach Cancer
A dual-energy CT radiomics model can better predict neoadjuvant chemotherapy response in locally advanced gastric cancer, impacting surgical decision-making. The dual-energy CT model achieved an AUC of 0.806 versus 0.729 with conventional CT in the training dataset (p = 0.041). High-risk patients identified by the dual-energy CT model had nearly double the overall survival and […]